OnCARlytics - Imugene
Alternative Names: CF33-CD19 - ImugeneLatest Information Update: 28 Jun 2025
At a glance
- Originator City of Hope National Medical Center
- Developer City of Hope National Medical Center; Imugene
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action CD19 antigen expression stimulants; Cell death stimulants; Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Solid-tumours in Australia (Intratumoural)
- 28 Jun 2025 No recent reports of development identified for preclinical development in Solid-tumours in Australia (IV)
- 02 Oct 2023 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural) (NCT06063317)